177Lu-Dotatate Improves PFS in Recurrent Meningioma

The primary end point of progression-free survival (PFS) was met when ¹⁷⁷Lutetium -Dotatate (Lutathera) was used to treat patients with refractory grade II/III meningioma, according to results from a phase 2 trial that was presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting.¹